Abstract
INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide and associated with decreased lung function and inflammation. The heterogeneity of COPD and its molecular and clinical features hinder efficient patient stratification and introduction of personalized therapeutic approaches. The available clinical tools do not efficiently predict the progression and exacerbations of the disease. Areas covered: An overview of the most recent studies on putative COPD protein biomarkers and the challenges for implementing their use in the clinical setting is presented. Expert commentary: Proteomics biomarker discovery in COPD has mostly focused on approaches evaluating specific proteins on a limited number of samples. The most promising protein candidates can be classified into five main biological categories: extracellular matrix (ECM) remodeling, inflammation/immune response, oxidative stress response, vascular tone regulation, and lipid metabolism. To efficiently stratify COPD patients and predict exacerbations, it will be necessary to implement biomarker panels to better represent the complex pathophysiology of this disease. The application of unbiased proteomics and bioinformatics followed by appropriate clinical validation studies will contribute to the achievement of this aim while increasing the number of validated biomarkers that can enter the qualification processes by the regulatory entities.
| Original language | English |
|---|---|
| Pages (from-to) | 37-45 |
| Number of pages | 9 |
| Journal | Expert Review Of Molecular Diagnostics |
| Volume | 19 |
| Issue number | 1 |
| Early online date | 18 Dec 2018 |
| DOIs | |
| Publication status | Published - 2 Jan 2019 |
Fingerprint
Keywords
- biomarkers
- COPD
- exacerbations
- mortality
- Protein biomarkers
- proteomics
Cite this
}
Systematic review on recent potential biomarkers of chronic obstructive pulmonary disease. / Aydindogan, Eda; Penque, Deborah; Zoidakis, Jerome.
In: Expert Review Of Molecular Diagnostics, Vol. 19, No. 1, 02.01.2019, p. 37-45.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Systematic review on recent potential biomarkers of chronic obstructive pulmonary disease
AU - Aydindogan, Eda
AU - Penque, Deborah
AU - Zoidakis, Jerome
PY - 2019/1/2
Y1 - 2019/1/2
N2 - INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide and associated with decreased lung function and inflammation. The heterogeneity of COPD and its molecular and clinical features hinder efficient patient stratification and introduction of personalized therapeutic approaches. The available clinical tools do not efficiently predict the progression and exacerbations of the disease. Areas covered: An overview of the most recent studies on putative COPD protein biomarkers and the challenges for implementing their use in the clinical setting is presented. Expert commentary: Proteomics biomarker discovery in COPD has mostly focused on approaches evaluating specific proteins on a limited number of samples. The most promising protein candidates can be classified into five main biological categories: extracellular matrix (ECM) remodeling, inflammation/immune response, oxidative stress response, vascular tone regulation, and lipid metabolism. To efficiently stratify COPD patients and predict exacerbations, it will be necessary to implement biomarker panels to better represent the complex pathophysiology of this disease. The application of unbiased proteomics and bioinformatics followed by appropriate clinical validation studies will contribute to the achievement of this aim while increasing the number of validated biomarkers that can enter the qualification processes by the regulatory entities.
AB - INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide and associated with decreased lung function and inflammation. The heterogeneity of COPD and its molecular and clinical features hinder efficient patient stratification and introduction of personalized therapeutic approaches. The available clinical tools do not efficiently predict the progression and exacerbations of the disease. Areas covered: An overview of the most recent studies on putative COPD protein biomarkers and the challenges for implementing their use in the clinical setting is presented. Expert commentary: Proteomics biomarker discovery in COPD has mostly focused on approaches evaluating specific proteins on a limited number of samples. The most promising protein candidates can be classified into five main biological categories: extracellular matrix (ECM) remodeling, inflammation/immune response, oxidative stress response, vascular tone regulation, and lipid metabolism. To efficiently stratify COPD patients and predict exacerbations, it will be necessary to implement biomarker panels to better represent the complex pathophysiology of this disease. The application of unbiased proteomics and bioinformatics followed by appropriate clinical validation studies will contribute to the achievement of this aim while increasing the number of validated biomarkers that can enter the qualification processes by the regulatory entities.
KW - biomarkers
KW - COPD
KW - exacerbations
KW - mortality
KW - Protein biomarkers
KW - proteomics
U2 - 10.1080/14737159.2018.1559054
DO - 10.1080/14737159.2018.1559054
M3 - Review article
VL - 19
SP - 37
EP - 45
JO - Expert Review Of Molecular Diagnostics
JF - Expert Review Of Molecular Diagnostics
SN - 1473-7159
IS - 1
ER -